Circulating sphingolipids in heart failure
Lack of significant advancements in early detection and treatment of heart failure have precipitated the need for discovery of novel biomarkers and therapeutic targets.Over the past decade, circulating sphingolipids have solo jec 10 elicited promising results as biomarkers that premonish adverse cardiac events.Additionally, compelling evidence dire